Navigation Links
Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
Date:2/11/2009

>

Amortization

Amortization for the three-month period ended December 31, 2008, increased $27,262 to $691,168 as compared to $663,906 for the three-month period ended December 31, 2007. For the six-month period ended December 31, 2008, amortization increased $159,173 to $1,482,397 as compared to $1,323,224 for the same period in fiscal 2008.

The three-month period increase in amortization expense is primarily due to the amortization expense relating to the compounds, technology and patents acquired from Forbes during the first quarter of fiscal 2009. The six-month period increase in amortization expense is due to increased amortization expense relating to the workforce acquired from Protana due to a workforce reduction, the full-quarter impact of amortizing the additional consideration paid to acquire the ENI technology in December, 2007 and the amortization expense resulting from the assets acquired from Forbes.

Interest Income, net

Interest income for the three-month period ended December 31, 2008 was $346,505 as compared to $692,552 for the same period in fiscal 2008, resulting in a decrease of $346,047. For the six-month period ended December 31, 2008, interest income was $760,129 as compared to $1,289,031 for the same period in fiscal 2007, resulting in a decrease of $528,902. The decreases in interest income resulted from decreased cash balances due to cash disbursements as well as decreases in effective interest rates.

    About Transition
    ----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discove
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Transition Therapeutics Announces Milestone Payment from Elan
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Pure Weight Loss Takes Additional Steps To Assure Seamless Transition For Clients
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Bisexuality not a transitional phase among women, according to new research
11. Transition of Behavioral Health Services from WPIC-BV to Heritage Valley Health System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 Not all ... they take care to make sure all their patients ... For some, this may include the newly-introduced online therapy. ... program which gives patients the opportunity to seek treatment ... can provide medical and clinical care at a distance. ...
(Date:9/16/2014)... Orlando, Florida (PRWEB) September 16, 2014 These ... the last 3 years to receive up to $10,000 in ... This program, as well as other state and federal programs, ... have to be paid back until you sell or move ... loan is a 0% interest loan. There are no monthly ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is excited to ... Gratafy for a fun evening of tech networking. , Seattle’s ... the growth of companies in these sectors, there’s also a need ... tech and at startups to connect with each other. As ... events for their peers to meet and mingle in fun, relaxed ...
(Date:9/16/2014)... TUESDAY, Sept. 16, 2014 (HealthDay News) -- Although magnesium ... for very preterm delivery, new research suggests it won,t ... analyzing the effects of magnesium sulfate given to pregnant ... on brain, behavioral, growth or functional outcomes among those ... 11 years old. The new findings don,t negate ...
(Date:9/16/2014)... A new clinical trial comparing the ... balloons (DEB) in treating in-stent restenosis (ISR) ... superior late angiographic results and better late ... today at the 26th annual Transcatheter Cardiovascular ... Cardiovascular Research Foundation (CRF), TCT is the ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Results of RIBS IV trial reported at TCT 2014 2
... 12, 2010 A strategic alliance announced today between ... significant advance personalized medicine. The partnership will create ... more rationally design and tailor their drugs to specific ... define a given disease. TD2 will use Horizon,s ...
... As alcohol consumption increases, so does risk for non-cancerous breast ... Frequent alcohol consumption by teenage girls may increase the chances ... and possibly breast cancer later in life. , Research published ... that girls who drank the most alcohol during their teen ...
... that smoking in cars is 23 times more toxic than ... CMAJ ( Canadian Medical Association Journal ) (pre-embargo link ... describes how a local media report of an unsourced statistic ... a vehicle than in a home"" led to widespread ...
... Exposure to an increased level of air pollutants, especially ... successful pregnancy among women undergoing in vitro fertilization, according ... team examined the outcomes of the first pregnancy attempt ... S. Hershey Medical Center, Hershey, Pa.; Shady Grove Fertility, ...
... women who drink alcohol increase their risk of benign ... Washington University School of Medicine in St. Louis and ... developing breast cancer. "Our study clearly showed that ... amount of alcohol consumed in this age group," says ...
... Most women scheduled for gynecologic surgery to address noncancerous ... not worried about the effects of the procedure on their ... planning to be sterilized did express concern in this study ... even though that surgery does not affect hormone levels. ...
Cached Medicine News:Health News:TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service 2Health News:Teen Drinking May Boost Breast Problems Later 2Health News:Teen Drinking May Boost Breast Problems Later 3Health News:Second-hand smoke toxicity in cars: Myth into fact 2Health News:Exposure to nitrogen dioxide lowers in vitro fertilization success 2Health News:Adolescent drinking adds to risk of breast disease, breast cancer 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 3Health News:Most women facing gynecologic surgery don't worry about its effects on sex 4
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... Amgen (Nasdaq: AMGN ) today announced ... had significantly greater adherence, compliance, and persistence during ... oral bisphosphonate commonly used to treat osteoporosis. ... compliance (a measure of how well patients follow ...
... March 23, 2011 NephRx Corporation today announced issuance ... novel growth factor peptide NX002 as a potential treatment ... NX002 may have applications in acute and chronic diseases ... colitis.  It has been shown to stimulate the growth ...
Cached Medicine Technology:Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 2Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 3Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 4Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 5Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 6Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 7Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 8Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 9Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 10Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 11NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
... reagent once reconstituted offers the laboratory all ... help maximize laboratory productivity, minimize operator error ... patented technology of the Infinity Urea (Nitrogen) ... and stability once reconstituted that will minimize ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... Triglycerides powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: